aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded as a part of Q² Solutions, Rules-Based Medicine (RBM) is a leading multiplexed biomarker testing laboratory. The company's core mission is to provide comprehensive protein biomarker products and services utilizing its proprietary Multi-Analyte Profiling (MAP) technology platform. RBM focuses on delivering reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes across multiple species. Their services cater primarily to pre-clinical and clinical researchers, offering cost-effective solutions for biomarker discovery and validation.
Notable affiliated individuals include experts in biomarker research and diagnostics, contributing to RBM's reputation as a world-leading CLIA-certified lab. Key achievements include the development of ultrasensitive immunoassays for neurodegenerative therapeutics and validated assays for idiopathic pulmonary fibrosis (IPF) clinical trials. RBM's impact is significant in advancing biomarker research, aiding in the diagnosis, monitoring, and therapeutic development for various diseases, thereby enhancing the precision and efficacy of medical research globally.
Operating Status
Acquired
Ownership Type(s)
Private
Main Product(s)
Biomarker Testing
Technology
Analytics
Tags
Biotech, API
Model Types
Software, Data
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Small Business
Geographic Exposure
Global
When was Rules-Based Medicine founded?
Rules-Based Medicine was founded in 2002.
Where is Rules-Based Medicine’s headquarters located?
Rules-Based Medicine’s headquarters is located in DE, US.
When was Rules-Based Medicine’s last funding round?
Rules-Based Medicine’s most recent funding round was for $25M (USD) in October 2007.
How many employees does Rules-Based Medicine have?
Rules-Based Medicine has 125 employees as of Feb 5, 2024.
How much has Rules-Based Medicine raised to-date?
As of July 05, 2023, Rules-Based Medicine has raised a total of $25M (USD) since Oct 15, 2007.
Add Comparison
Total Raised to Date
$25M
USD
Last Update Oct 15, 2007
Last Deal Details
$25M
USD
Oct 15, 2007
Series A
Total Employees Over Time
125
As of Feb 2024
Rules-Based Medicine Address
Delaware
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts